Bristol Myers Squibb Surpasses Profit Expectations: Eliquis and Cancer Medicines Drive Growth

Bristol Myers Squibb exceeded Wall Street's first-quarter profit expectations with strong sales of blood thinner Eliquis and newer cancer treatments. Despite declines in some areas, the company's growth portfolio rose significantly. Efforts in AI and cost-cutting support future investment and development, as revenue targets remain optimistic.

Bristol Myers Squibb outperformed Wall Street estimates in the first quarter of the year, boosted by robust growth from its blood thinner Eliquis and newer cancer treatments. The pharmaceutical giant's adjusted earnings reached $1.58 per share, outpacing analyst predictions of $1.42 according to LSEG data, while revenues soared to $11.49 billion, surpassing the expected $10.9 billion.

Eliquis, co-marketed with Pfizer, saw a remarkable 16% increase in quarterly sales, totaling $4.14 billion. Demand for the blood thinner remains robust, with new prescription shares exceeding 75%, affirmed Chief Commercialization Officer Adam Lenkowsky, noting that this momentum is anticipated to sustain growth throughout the year.

Despite a decline in some older products due to generic competition, growth from newer cancer medications contributed to an overall 12% rise in Bristol Myers' growth portfolio sales, hitting $6.23 billion. Challenges remain with certain products, yet the company remains focused on strategic innovations, including the expansion of artificial intelligence across its R&D efforts.